Phillip Price

senior associate

Background

Phillip is a European Patent Attorney and  a UK Chartered Patent Attorney. He joined Dehns in 2006 after graduating from the University of Oxford with a Masters degree in Molecular and Cellular Biochemistry. Phillip handles a diverse range of work in the biotechnology and life sciences fields and was made a Senior Associate in 2019.

 

Type of clients and client work

The majority of Phillip’s clients are small/medium sized companies and technology transfer offices. He appreciates that his clients require clear advice that is genuinely relevant to their particular commercial situation. He advises on all aspects of the patent process and actively manages global patent portfolios.

He has particular experience in developing IPR portfolios and IP strategies from scratch. This initially involves working closely with each client to identify their patentable inventions. He enjoys drafting and guiding patent applications through examination to secure robust, useful patent protection in the markets of interest to his clients.

Phillip also handles freedom to operate issues, monitors and challenges competitor patents, advises on patent infringement and enforcement issues and handles post-grant proceedings at the EPO.

He works with both R&D-based companies and scientific service providers with innovative technologies. His clients include companies in both the pharmaceutical and medical device sectors. Phillip represents a number of SMEs whose income streams depend heavily on the licensing of patent-protected technologies, so he appreciates the commercial importance of obtaining high-quality patents.

 

Expertise

Phillip handles a diverse range of inventions in the biotechnology field, from a variety of human and animal therapies to transgenic microorganisms and industrial biotech processes. Areas of particular experience include biomaterials, biologics, drug discovery assays, diagnostics, blue biotech, oncology, glycobiology and synthetic biology. He also works with a number of innovative companies in the fields of cosmetics, nutraceuticals and human and animal nutrition.

 

Qualifications and Memberships

  • UK Chartered Patent Attorney, 2010
  • European Patent Attorney, 2010
  • Certificate in IP Law, Brunel University, 2007
  • Fellow of the Chartered Institute of Patent Attorneys
  • Member of the European Patent Institute

 

Higher Education

MBioch, Molecular and Cellular Biochemistry, 2006, University of Oxford

 

Other

Phillip was recognised as a “rising star” in the 2018, 2019 and 2020 editions of Managing Intellectual Property’s IP Stars publication.

Many of Phillip’s clients are based in Scandinavia. He is a frequent visitor to Aleap, Norway Healthtech and the Oslo Cancer Cluster.

Phillip is a regular contributor of articles to the Dehns website. See below for his articles on a wide range of IP and biotechnology topics and issues.

Contact details

The Brinell Building
30 Station Street
Brighton
BN1 4RB
United Kingdom
+44 (0)1273 244 200

Department

biotechnology

Articles by Phillip Price

The CRISPR-Cas9 Decision in a nutshell The CRISPR-Cas9 Decision in a nutshell 17 Feb 2017 6 min read The Patentability of Diagnostic Inventions in Europe, Canada and the US – webinar The Patentability of Diagnostic Inventions in Europe, Canada and the US – webinar 23 Jul 2020 2 min read It’s nothing personal: large spike in objections to personalised medicine patents It’s nothing personal: large spike in objections to personalised medicine patents 22 Aug 2016 4 min read Is the Patent Box working for SMEs? Is the Patent Box working for SMEs? 04 Oct 2016 5 min read Does the Patent Box deliver? Does the Patent Box deliver? 28 Jul 2016 5 min read Going nowhere fast with the USPTO’s “Patents 4 Patients” program Going nowhere fast with the USPTO’s “Patents 4 Patients” program 07 Jul 2016 4 min read Innovate UK to merge with research councils – a good thing for UK science? Innovate UK to merge with research councils – a good thing for UK science? 10 Jun 2016 4 min read Diagnostic methods become more difficult to patent in Canada Diagnostic methods become more difficult to patent in Canada 17 Jun 2016 4 min read All scientific papers to be open access by 2020? All scientific papers to be open access by 2020? 02 Jun 2016 4 min read How problematic are irreproducible results for patentees? How problematic are irreproducible results for patentees? 27 May 2016 4 min read What can companies without a blockbuster drug learn from the latest Humira patent challenge? What can companies without a blockbuster drug learn from the latest Humira patent challenge? 20 May 2016 4 min read New model of human gut to shed light on role of gut microbiota in disease New model of human gut to shed light on role of gut microbiota in disease 11 May 2016 3 min read “Second Skin” technology: therapeutic, cosmetic and UV-barrier applications. “Second Skin” technology: therapeutic, cosmetic and UV-barrier applications. 10 May 2016 3 min read IP ownership: An incentive for academics? IP ownership: An incentive for academics? 09 May 2016 3 min read